<DOC>
	<DOCNO>NCT01152619</DOCNO>
	<brief_summary>This multi-center , randomize , observer-blinded , placebo-controlled study evaluate safety tolerability subcutaneous dos RO4989991 patient allergic rhinitis otherwise healthy . The anticipated time study treatment 2 week .</brief_summary>
	<brief_title>A Study RO4989991 Patients With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Adult patient , 1865 year age , inclusively A history allergic rhinitis diagnose physician , otherwise healthy A positive skin prick test least one standardized allergen screen A body mass index ( BMI ) 18 32 kg/m2 , inclusively History presence respiratory disease condition allergic rhinitis Use prescription medication herbal remedy within 14 day dose study drug Use overthecounter ( OTC ) medication within 7 day dose study drug Acute infection ( include viral infection ) 6 week ( 8 week respiratory infection ) precede dose ongoing chronic infection Positive test human immunodeficiency virus ( HIV ) hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>